Last Updated : May 26, 2025
Details
Generic Name:
olaparib
Project Status:
Not filed
Therapeutic Area:
BRCA-mutated (gBRCAm) metastatic adenocarcinoma
Manufacturer:
Astra Zeneca Canada inc.
Brand Name:
Lynparza
Project Line:
Reimbursement Review
Project Number:
NS0042-000
Biosimilar:
No
Fee Schedule:
N/A
Indications:
Monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.
Recommendation Type:
Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission.
Last Updated : May 26, 2025